GLP-1 Drugs & Athletes | Performance Risks & Fueling Tips

The Hidden Conflict Between Weight Loss Drugs and Performance

Tyler Brown pedaled his stationary bike during a virtual race, alarm set to ensure he consumed sugar every 15 minutes. He was taking retatrutide, a GLP-1 receptor agonist that significantly dampened his appetite. Without this strict fueling schedule, he risked bonking during his two-hour sessions. The medication helped the 41-year-old drop from 298 pounds to 190, but it fundamentally changed how he manages his athletic output. He now tracks every calorie, treating food like medicine rather than a source of joy.

Millions of Americans rely on GLP-1 medications like Ozempic and Wegovy to manage obesity and diabetes. While these drugs are effective, they pose unique challenges for active individuals. They mimic natural hormones to slow digestion and signal fullness. This chemical shift can create a dangerous gap for athletes who need consistent caloric intake to sustain high-intensity training. Research indicates that 25 to 40 percent of weight lost on these drugs consists of lean tissue rather than fat, a reality that compromises muscle power.

The Physiological Toll of Underfueling

Athletes training more than five hours per week while in a calorie deficit face the risk of relative energy deficiency. This state happens when the body lacks the fuel necessary to support the energy it expends. The long-term effects of this imbalance extend far beyond simple muscle loss. Experts report that bodily systems begin to slow down when they lack sufficient energy. This can lead to gastrointestinal issues, hormonal imbalances, and increased susceptibility to injury.

Beyond the physical, users report shifts in their psychological relationship with exercise. Brown described experiencing anhedonia, or a loss of interest in the activities that previously motivated him. He found himself lacking the drive to pursue heavy lifts he once enjoyed, such as his goal to join the 1,000-pound club. While he remains satisfied with his weight loss, he acknowledges that his absolute athletic performance has hit a ceiling. The trade-off between aesthetic goals and physical peak performance is becoming a central point of discussion among endurance coaches.

Managing Fitness Goals While on Medication

Safety remains the primary concern for any athlete using these drugs. Kylee Van Horn, an endurance coach at FlyNutrition, warns that intentional calorie restriction and peak performance are rarely compatible. She suggests that athletes prioritize protein intake to counteract muscle loss. Aiming for one gram of protein per pound of target body weight is a common recommendation, though consuming this much can be difficult when the drug suppresses hunger. It requires a deliberate, often uncomfortable effort to eat enough to sustain muscle mass.

Timing becomes an essential component of training management. Because GLP-1 effects are strongest shortly after injection, some physicians recommend scheduling doses far from critical training days or race events. Adjusting the dosage is another option for those who reach their goal weight. By tapering to a maintenance level, individuals may experience less severe appetite suppression, allowing for better fueling. For some, the most viable path is pausing medication use entirely during intense training cycles or preparation for a major event. This ensures the body is capable of handling the demands of high-level athletic effort without the constant threat of depletion or injury.